{"id":97636,"date":"2025-08-15T01:14:07","date_gmt":"2025-08-15T01:14:07","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/"},"modified":"2025-08-15T01:14:07","modified_gmt":"2025-08-15T01:14:07","slug":"24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/24-7-market-news-lixte-biotech-advances-precision-oncology-pipeline-with-first-phase-1b-2-trial-readout-expected-in-2h-2025\/","title":{"rendered":"24\/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B\/2 Trial Readout Expected in 2H 2025"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p><strong><em>Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer<\/em><\/strong><\/p>\n<p><strong>24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title<\/strong><\/p>\n<p>DENVER, Aug.  14, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DiazhYmLoOb8Jb4CqLHpwKA64TksZaRUdXBltGwMZtJOw8VUFUV98dDqyfCMBkws0TsBid_Jz0iJuDF_jZjUxhACDChtme45gNH_Nqe7e3KAKYODkvMOLaRz2GFp4EFC\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>247marketnews.com<\/u><\/a>, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways.<\/p>\n<p>2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity.<\/p>\n<p><strong>Upcoming Catalysts: Anticipated Trial Results in 2H 2025<\/strong><\/p>\n<p><strong>1B\/2 Trial \u2013 Ovarian Clear Cell Carcinoma (OCCC)<\/strong><\/p>\n<p>Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5\u201310% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality.<\/p>\n<p>The Phase 1B\/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100\u2019s synergistic enhancement of immune checkpoint blockade.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Status:<\/strong> Enrolled, with interim safety completed<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Upcoming Milestone:<\/strong> Preliminary safety and efficacy data expected Q4 2025<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Potential Market Impact:<\/strong> Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies<\/li>\n<\/ul>\n<p><strong>1B\/2 Trial \u2013 Advanced Soft Tissue Sarcoma (STS)<\/strong><\/p>\n<p>Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor.<br \/>LIXTE\u2019s Phase 1B\/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Status:<\/strong> Dose escalation completed.<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Upcoming Milestone:<\/strong> Safety report Q4 2025<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Potential Market Impact:<\/strong> The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need<\/li>\n<\/ul>\n<p><strong>1B Trial \u2013 Metastatic Microsatellite Stable (MSS) Colon Cancer<\/strong><\/p>\n<p>MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors.<\/p>\n<p>LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Status:<\/strong> Trial open, first patients recruited<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Potential Market Impact:<\/strong> The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases<\/li>\n<\/ul>\n<p><strong>Platform Potential and Market Opportunity<\/strong><\/p>\n<p>LIXTE\u2019s strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform\u2019s potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Strong IP Position<\/strong>: Multiple issued and pending patents covering composition, methods of use, and combinations<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Pipeline Expansion<\/strong>: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma.<\/li>\n<li style=\"margin-top:5pt; margin-bottom:5pt;\"><strong>Partnership Potential<\/strong>: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities<\/li>\n<\/ul>\n<p>Contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ty9gxPNh-TdGA21ywOt8c0_YMuiO0s355lyGyBp2dZLNPT7G0BLzOV0o6LPhSyZZ93-45BbEqblgfSYTcelm2dco4_caLixc105o3eeYszTDkvntUtc8trtWJnnOqjXt\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sales@247marketnews.com<\/u><\/a> for Analyst Report coverage and other investor\/public relations services.<\/p>\n<p><strong>About LIXTE Biotechnology Holdings, Inc.<\/strong><\/p>\n<p>LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company\u2019s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.<\/p>\n<p>More information can be found at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q8uW0Ye_T_9C8uTxoubsTYQdRIJQlZ0rj2XsZKUq9LJc0Ob1QGCi1qoYqjb_PgxQIJ8ywsYj4NR_WLJPWV5c6Q==\" rel=\"nofollow\" target=\"_blank\" title=\"www.lixte.com\">www.lixte.com<\/a><\/p>\n<p><strong>24\/7 MARKET NEWS, INC Disclaimer<\/strong><br \/>Please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9iQMmNBxxPXp8WP_LuNRVBm2xPwfvQgHJwa-dcOb3_cs9HnNVpuwUBNhAzzZY4fAgVm_3ggrofwhJnidlQ95OUZV7lEsD9V7g3zIcFOxhsQeOi-lRgoSaHBH390WRpDh1B2O68M0SzCvzoZrqGCcPINhcAqFmtd3fMFj8AjgY04=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/247marketnews.com\/lixte-biotechnology\/<\/a> for further LIXT information and 247marketnews.com LIXT disclosure information.<\/p>\n<p><strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><\/p>\n<p>This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company&#8217;s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;estimates,&#8221; &#8220;aims,&#8221; &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;potential&#8221; or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company&#8217;s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company&#8217;s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.<\/p>\n<pre\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24\/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) &#8212; 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":97637,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/712f65d0-792c-4a6a-ad16-7690d6545107","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-97636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/97636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=97636"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/97636\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/97637"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=97636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=97636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=97636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}